Credit Suisse Previews Affimed Therapeutics (AFMD) AFM13-NK Data Presentation on 4/9
Tweet Send to a Friend
Credit Suisse analyst Brad Canino reiterated an Outperform rating and $15.00 price target on Affimed Therapeutics (NASDAQ: AFMD) ahead of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
